Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE®1 (deferasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.S.
Deferasirox Tablets for Oral Suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older.
“We’re proud to offer an affordable generic treatment option with the launch of Deferasirox Tablets for Oral Suspension in the U.S.,” said Brendan O’Grady, EVP and Head of North America Commercial. “We continue striving to enable access to medicines for people living with chronic, complex conditions.”
With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
EXJADE® had annual sales of $134 million in the U.S., according to IQVIA data as of December 2018.
About Deferasirox Tablets for Oral Suspension
Deferasirox Tablets for Oral Suspension are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Limitations of Use: Controlled clinical trials of deferasirox with myelodysplastic syndromes (MDS) and chronic iron overload due to blood transfusions have not been performed. The safety and efficacy of deferasirox when administered with other iron chelation therapy have not been established.
IMPORTANT SAFETY INFORMATION
WARNING: Renal Failure, Hepatic Failure, and Gastrointestinal Hemorrhage. Deferasirox can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders. Deferasirox can cause hepatic injury including hepatic failure and death. Deferasirox can cause gastrointestinal (GI) hemorrhages, which may be fatal, especially in elderly patients who have advanced hematologic malignancies and/or low platelet counts.
Deferasirox is contraindicated in patients with: estimated GFR less than 40 mL/min/1.73m2; poor performance status; high-risk myelodysplastic syndromes; advanced malignancies; platelet counts less than 50 x 109/L; or known hypersensitivity to deferasirox or any component of deferasirox tablets for oral suspension.
Nonfatal upper GI irritation, ulceration and hemorrhage have also been reported in patients, including children and adolescents, receiving deferasirox. The risk of gastrointestinal hemorrhage may be increased when administering deferasirox in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. There have been reports of ulcers complicated with gastrointestinal perforation (including fatal outcome). Neutropenia, agranulocytosis, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox. Preexisting hematologic disorders may increase this risk.
Deferasirox has been associated with serious and fatal adverse reactions in the postmarketing setting among adults, predominantly in elderly patients. Deferasirox has been associated with serious and fatal adverse reactions in pediatric patients in the postmarketing setting. Deferasirox may cause serious hypersensitivity reactions (such as anaphylaxis and angioedema), with the onset of the reaction usually occurring within the first month of treatment. Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) which could be life-threatening or fatal have been reported during deferasirox therapy. Cases of erythema multiforme have been observed. Rashes may occur during deferasirox treatment.
Auditory disturbances (high frequency hearing loss, decreased hearing), and ocular disturbances (lens opacities, cataracts, elevations in intraocular pressure, and retinal disorders) were reported at a frequency of less than 1% with deferasirox therapy in the clinical studies. The frequency of auditory adverse events irrespective of causality was increased among pediatric patients who received deferasirox doses greater than 25 mg/kg/day when serum ferritin was less than 1,000 mcg/L.
In clinical trials of patients with transfusional iron overload, the most frequently occurring (greater than 5%) adverse reactions for deferasirox were diarrhea, vomiting, nausea, abdominal pain, skin rashes, and increases in serum creatinine.
For more information, please see accompanying Full Prescribing Information, including the Boxed Warning. A copy may be requested from Teva US Medical Information at 888-TEVA-USA (888-838-2872), email@example.com, or Teva’s Public Relations or Investor Relations contacts.
1 EXJADE® is a registered trademark of Novartis Pharmaceuticals Corporation
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 43,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch and potential benefits of the generic version of EXJADE ® , which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2018, including the sections thereof captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information.
Kevin C. Mannix
972 (3) 926-7516
972 (54) 888 5898